The notification has been sent to the Central Pollution Control Board, Expert Appraisal Committee and pollution control boards in all states and Union territories.
Moneycontrol's Sakshi Batra does a 3-Point Analysis to understand what it means for the Indian pharma industry.
The expected growth in the next financial year is on the back of healthy demand from the domestic market given increasing spend on healthcare along with improving access, Icra said in a statement.
Shraddha Sharma gets in conversation with Corporate Bureau Chief Prince Thomas to find out the expectations of the phama sector from Finance Minister Nirmala Sitharaman in Budget 2020.
“These companies have launched formulations by altering a scheduled formulation with strength/dosage other than as specified in DPCO, 2013 and secondly in combination with other non-scheduled medicines without even applying for price approval from NPPA as required under Para 1 (2) of DPCO, 2013,” NPPA said.
Here's what happened in pharma last week
R&D/clinical trial services performed in India are liable to service tax at the rate of 15% even when the recipient of service is situated outside India. To lower the cost of provision of such services and to boost innovation in the country and make such services globally competitive, it is important to provide for some sort of exemption.
A Democrat sweep in US polls may pose even greater pricing challenges for the pharma industry and pave the way for tighter pricing regulations for both brand name and generic drugs, according to a report.
The Central Board Of Direct Taxation (CBDT) has now extended the time period for consultation to December 31.
With the National List of Essential Medicines (NLEM) estimated to cover almost 20 percent of the Rs 72,800 crore domestic formulation business, an expected price cut of 15-20 percent will erode the market by 3-4 percent, the ICRA report said.
2012 was occupied by Pharma industry bodies & patient groups debated over the contours of the pricing policy. Essential drugs are getting cheaper. The Pharma pricing policy that was drafted towards the end of 2011 was just the tip of the iceberg which melted into a veritable deluge.
The pharma industry is on the edge of its seat with all eyes on the April 4 Group of Ministers (GoM) meeting which will decide on a final pricing policy for essential drugs, reports CNBC-TV18's Archana Shukla.
Union health ministry's plan to bring 348 drugs of the National List of Essential Medicines (NLEM) under price control is facing stiff resistance from the pharma industry, reports the Times of India.
Pfizer, the Indian unit of drug maker Pfizer Inc, is eyeing a 13-14% growth in its revenues in the financial year 2011-12, a senior company official said today.